Bruker Co. (NASDAQ:BRKR) Receives $50.23 Consensus Target Price from Analysts

Shares of Bruker Co. (NASDAQ:BRKR) have been assigned an average rating of “Buy” from the seventeen analysts that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $50.23.

A number of research firms recently commented on BRKR. ValuEngine upgraded Bruker from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Stifel Nicolaus began coverage on Bruker in a research report on Thursday, November 14th. They set a “hold” rating and a $53.00 price objective for the company. Needham & Company LLC began coverage on Bruker in a research report on Friday, January 3rd. They set a “strong-buy” rating and a $39.00 price objective for the company. Wells Fargo & Co began coverage on Bruker in a research report on Tuesday, January 7th. They set an “overweight” rating and a $60.00 price objective for the company. Finally, Citigroup began coverage on Bruker in a research report on Monday, January 6th. They set a “buy” rating and a $52.00 price objective for the company.

A number of large investors have recently modified their holdings of the business. FMR LLC boosted its stake in Bruker by 27.6% in the 4th quarter. FMR LLC now owns 16,599,624 shares of the medical research company’s stock worth $846,082,000 after buying an additional 3,588,867 shares during the last quarter. State Street Corp boosted its stake in Bruker by 2.6% in the 4th quarter. State Street Corp now owns 1,458,346 shares of the medical research company’s stock worth $74,332,000 after buying an additional 37,148 shares during the last quarter. TD Asset Management Inc. boosted its stake in Bruker by 19.5% in the 4th quarter. TD Asset Management Inc. now owns 844,950 shares of the medical research company’s stock worth $43,067,000 after buying an additional 138,069 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Bruker by 0.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 787,840 shares of the medical research company’s stock worth $40,157,000 after buying an additional 3,317 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Bruker by 152.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 761,292 shares of the medical research company’s stock worth $38,803,000 after buying an additional 459,986 shares during the last quarter. 68.58% of the stock is currently owned by hedge funds and other institutional investors.

Bruker stock traded down $0.08 during midday trading on Friday, reaching $50.51. 410,718 shares of the company were exchanged. The firm’s 50-day simple moving average is $51.39 and its 200-day simple moving average is $47.07. Bruker has a 1 year low of $36.51 and a 1 year high of $54.49.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Read More: Price to Earnings Ratio (PE) Basics

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit